216 results on '"Nadal, E."'
Search Results
2. 72P Prevalence and potential consequences of drug-drug interactions in oncohematological patients treated with oral antineoplasic drugs
3. EE71 Cost-Effectiveness Analysis of Using Foundationone Liquid CDx in Patients With Advanced Non-Small Cell Lung Cancer in Whom Tissue-Based Testing Is Not Feasible
4. 115TiP MDT-BRIDGE: A phase II study of neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery and adjuvant D or chemoradiotherapy (CRT) and consolidation D in patients (pts) with resectable or borderline resectable stage IIB–IIIB NSCLC
5. Molecular profiling and feasibility using a comprehensive hybrid capture panel on a consecutive series of non-small-cell lung cancer patients from a single centre
6. P1.01-01 Frequency of Germline Mutations in Patients with Non-small Cell Lung Cancer (NSCLC) Harboring Actionable DRIVER Alterations (G-DRIVER)
7. EP08.03-01 Copy Number Variants and Late Somatic Mutations Underlying Tumor Progression in NADIM Clinical Trials
8. P1.27-07 BRAF Mutations Identify Non-small-Cell Lung Cancer Patients Who Benefit from Neoadjuvant Chemo-Immunotherapy
9. Manifold learning for coherent design interpolation based on geometrical and topological descriptors
10. Advanced Methodologies for Topology and Geometry Optimization of Noise Control Devices
11. 3D Topology Optimization with h-adaptive Refinement Using Cartesian Grids Finite Element Method (cgFEM)
12. Mitigation of Railway Wheel Rolling Noise by Using Advanced Optimization Techniques
13. Digital Volume Correlation techniques for patient-specific simulation of vertebrae with metastasis
14. 2MO First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in metastatic non-small cell lung cancer (mNSCLC): Clinical outcomes and biomarker analyses from CheckMate 592
15. Bone remodelling-based numerical evaluation of personalized masticatory forces from CT-scans
16. Incidence of drug-drug interactions of QT-prolonging drugs in an onco-hematological outpatient
17. P2.14-04 Re-Definition of Lung Adenocarcinoma Transcriptional Subtypes Using Integrative Bioinformatics Approaches
18. P16.01.A Factors predicting cognitive impairment after intrathecal methotrexate treatment in patients with non-small cell lung cancer and leptomeningeal disease
19. PL03.12 Progression Free Survival and Overall Survival in NADIM II Study
20. OA02.03 Tumor Bulk-RNA Seq Identifies Patients at High Risk of Progression in Non-complete Pathological Responders from NADIM Trial
21. MA06.03 Pre-treatment ctDNA Levels Significantly Predicts of OS and PFS in NADIM II Trial
22. EP08.01-029 NIVIPI-BRAIN, A Phase II Study of Nivolumab plus Ipilimumab Combined with Chemotherapy for Patients with NSCLC and Synchronous Brain Metastases
23. OA07.06 Second Line Treatment Outcomes After Progression on Immunotherapy Plus Chemotherapy (IO-CT) In Advanced Non-small Cell Lung Cancer (aNSCLC)
24. EP16.03-027 Routine Molecular Testing Using the TSO500+ NGS Panel in a Cohort of Patients with NSCLC
25. P1.09-03 Multidisciplinary Thoracic Tumors Board Survey in Spain
26. 939P Changes in immune gene signatures after neoadjuvant chemoimmunotherapy treatment in NSCLC patients from NADIM trial
27. LBA52 Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study
28. P2.07-02 RET Fusion Testing with FISH and Real-Time PCR: a Comparison with RNA-Based Next-Generation Sequencing in RET Positive NSCLC
29. EP08.01-090 Association of Gender and Outcomes in Patients With Advanced NSCLC Treated With Immunotherapy Alone or in Combination With Chemotherapy Upfront
30. EP08.01-091 Association of dNLR Score with Outcomes in Patients with Advanced NSCLC Under Immunotherapy Alone +/- Chemotherapy Upfront
31. 1630P Effectivity and safety of anti-SARS-CoV2 vaccination in patients with lung cancer: The VAC-CaP observational study (GECP 21/01)
32. Stress-Based Femur Fracture Risk Evaluation from Bone Densitometry
33. Estimating the Patient-Specific Relative Stiffness Between a Hepatic Lesion and the Liver Parenchyma
34. Allying topology and shape optimization through machine learning algorithms
35. Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC—a systematic review and meta-analysis
36. 32P Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC: A systematic review and meta-analysis
37. 157MO Immune gene signatures for predicting pathological response of NSCLC patients treated with neoadjuvant chemoimmunotherapy
38. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
39. POSC61 Cost-Effectiveness of ROS1-Testing Strategy Compared to a NO-ROS1-Testing Strategy in Advanced NSCLC in Spain
40. Fundaments of Recovery-Based Error Estimation and Bounding
41. OA09.02 Atezo-Brain: Single Arm Phase II Study of Atezolizumab Plus Chemotherapy in Stage IV NSCLC With Untreated Brain Metastases
42. OA20.02 Pre-Treatment Levels of ctDNA for Long-Term Survival Prediction in Stage IIIA NSCLC Treated With Neoadjuvant Chemo-Immunotherapy
43. P47.09 Tepotinib + Osimertinib for EGFR-Mutant NSCLC with Resistance to First-Line Osimertinib Due to MET amplification: INSIGHT 2
44. MA14.02 RET Fusion Testing in Advanced Non-Small Cell Lung Carcinoma Patients: the RETING Study
45. P50.01 RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19-del Variants
46. OA20.01 Long Term Survival in Operable Stage Iiia Nsclc Patients Treated With Neoadjuvant Nivolumab Plus Chemotherapy - Nadim Study
47. 1315P Impact of high fasting plasma glucose in the clinical outcome of patients with advanced NSCLC with PD-L1 ≥ 50% treated with frontline pembrolizumab
48. 1272P First results of the early onset lung cancer (EOLUNG) study to characterize genomic alterations using FoundationOne CDx in young patients with non-small cell lung cancer
49. 1172MO Durvalumab consolidation in patients with stage III non-resecable NSCLC with driver genomic alterations
50. 1366TiP Tepotinib + osimertinib for EGFR-mutant NSCLC with resistance to first-line osimertinib due to MET amplification (METamp): INSIGHT 2
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.